Elutia Secures $15 Million Loan Financing from Avenue Capital Group to Fund NXT-41x Launch in $1.5 Billion Plastic and Reconstructive Surgery Market

Elutia (Nasdaq: ELUT) entered into a $15 million growth capital loan financing with Avenue Capital Group to support development and commercialization of NXT-41x, its next-generation antibiotic-eluting biomatrix for plastic and reconstructive surgeries.

Rhea-AI Summary

Elutia (Nasdaq: ELUT) entered into a $15 million growth capital loan financing with Avenue Capital Group to support development and commercialization of NXT-41x, its next-generation antibiotic-eluting biomatrix for plastic and reconstructive surgeries. According to Elutia, $10 million was funded at closing, with a second $5 million tranche available upon FDA 510(k) clearance of NXT-41x.

NXT-41x is aimed at reducing post-operative infection rates, which the company notes can be as high as 15–20% in complex plastic and reconstructive procedures, including breast reconstruction. Elutia estimates a $1.5 billion U.S. market opportunity and anticipates FDA clearance in the first half of 2027, positioning this financing to help fund a future commercial launch.

Positive

• $15 million growth capital facility secured to fund NXT-41x development and launch
• $10 million funded immediately at closing, extending Elutia’s cash runway
• Additional $5 million tranche tied to NXT-41x FDA 510(k) clearance milestone
• Financing structure achieved without an equity offering, avoiding immediate share dilution
• Targeting an estimated $1.5 billion U.S. plastic and reconstructive surgery market

Negative

• Second $5 million tranche is contingent on FDA 510(k) clearance of NXT-41x
• NXT-41x remains pre-clearance, with FDA decision only anticipated in H1 2027

News Explained

The newly announced financing is loan-based, and Elutia says it proceeds without an equity offering; under the supplied dilution definition, this announcement discloses no new-share dilution for existing holders, while $10 million is funded now and the remaining $5 million remains conditional.

Argus Aug 14 session 1 alert

+6.02% close to close 0.0x rel. volume Open Argus

Details

News Market Reaction – ELUT

$41.61M Market Cap

On Aug 14, the first trading day after this news, ELUT closed 6.02% above the previous close.

Data tracked by StockTitan Argus for the Aug 14 session.

Key Figures

Initial funding: $10 million Second tranche: $5 million Total financing: $15 million +3 more

Initial funding

$10 million

Funded at closing

Second tranche

$5 million

Unlocked upon FDA 510(k) clearance of NXT-41x

Total financing

$15 million

Growth capital financing agreement with Avenue Capital

U.S. market opportunity

$1.5 billion

Plastic and reconstructive surgery market

Anticipated FDA clearance

First half of 2027

NXT-41x 510(k) clearance

Post-operative infection rates

15–20%

Multiple complex plastic and reconstructive surgical procedures

Historical Context

5 past events · Latest: Jul 31

5 events

1. Jul 31

   Earnings date notice

   24h Move

   -5.3%

   Announced timing for second-quarter financial results and investor conference call

2. Jul 16

   Asset sale agreement

   24h Move

   +0.0%

   Signed SimpliDerm sale agreement intended to strengthen balance sheet without equity dilution

3. Jun 11

   Investor presentation

   24h Move

   +0.4%

   Scheduled presentation covering biomatrix technology and post-surgical infection applications

4. May 18

   Inducement awards

   24h Move

   +1.8%

   Granted stock options to one new employee under Nasdaq inducement award rules

5. May 14

   Quarterly earnings report

   24h Move

   -1.0%

   Reported quarterly sales growth and operating progress alongside a continuing net loss

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

510(k) clearance, antibiotic-eluting biomatrix, growth capital financing, equity offering

4 terms

510(k) clearance regulatory

"second $5 million tranche unlocked upon FDA 510(k) clearance of NXT-41x"

A 510(k) clearance is a U.S. regulatory approval that lets a medical device be sold because it is shown to be substantially similar to an already-legal device; think of it as a passport saying the new product is close enough to a known item to enter the market without a full, lengthy review. For investors, 510(k) clearance signals faster, lower-cost market access and reduced regulatory risk compared with new, untested device pathways, which can materially affect timelines, costs and revenue prospects.

antibiotic-eluting biomatrix medical

"commercialization of Elutia's next-generation antibiotic-eluting biomatrix"

A soft or solid medical material that either coats an implant or is placed in a wound and slowly releases antibiotics over time to prevent or treat infection. Think of it as a slow-release bandage or sponge that delivers drugs where they are needed instead of relying on pills. For investors, this matters because the approach can improve patient outcomes, influence regulatory approval and reimbursement, and create commercial differentiation or liability risks that affect a product’s market value.

growth capital financing financial

"announced a $15 million growth capital financing agreement"

Growth capital financing is money provided to an established company to help it expand—think of it as fuel to open new locations, develop products, hire staff, or enter new markets rather than to cover day-to-day bills. For investors it matters because it can accelerate revenue and profits, change ownership stakes or debt levels, and signal management’s confidence; these effects influence future valuation and potential returns much like adding horsepower to a car increases its speed and range.

equity offering financial

"funding commercialization of Elutia's next-generation antibiotic-eluting biomatrix without an equity offering"

An equity offering is when a company sells new shares to investors to raise money, similar to cutting a larger pizza into more slices to bring to a party. It matters because it changes ownership stakes — existing shareholders own a smaller portion of the company after the sale — and can affect the stock price and future profits depending on how the raised funds are used.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• $10 million funded at closing; second $5 million tranche unlocked upon FDA 510(k) clearance of NXT-41x
• Preserves shareholder value by funding commercialization of Elutia's next-generation antibiotic-eluting biomatrix without an equity offering
• NXT-41x targets the 15–20% post-operative infection rates in multiple complex plastic and reconstructive surgical procedures
  

GAITHERSBURG, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced a $15 million growth capital financing agreement with Avenue Capital Group (“Avenue Capital”). The transaction strengthens Elutia’s balance sheet and funds the continued development and commercialization of NXT-41x, the Company’s next-generation antibiotic-eluting biomatrix for plastic and reconstructive surgeries.

NXT-41x is designed to address a significant unmet medical need in plastic and reconstructive surgery, representing an estimated $1.5 billion U.S. market opportunity. U.S. Food and Drug Administration (“FDA”) clearance for NXT-41x is anticipated in the first half of 2027.

“This financing strengthens our balance sheet and allows us to continue advancing NXT-41x toward FDA clearance and commercial launch,” said Matt Ferguson, Chief Financial Officer of Elutia. “The $10 million we closed on this week significantly extends our runway, and the facility is expected to provide access to an additional $5 million exactly when it will be most useful — powering a strong NXT-41x launch and helping us reach as many patients as possible. NXT-41x brings to life our mission of humanizing medicine so patients can thrive without compromise, reducing the risk of complications for patients undergoing procedures where post-operative infection rates remain as high as 15–20%.”

“We are very pleased to partner with Elutia on this financing to help fund the Company’s next chapter of growth,” said Chad Norman, Senior Portfolio Manager with Avenue Capital. “We conducted a robust diligence process and were struck by the potential of NXT-41x to redefine soft tissue reinforcement for women needing reconstruction after breast cancer. We are excited to be part of Elutia’s journey and look forward to the clinical impact its technology will have.”

About Elutia
Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can be identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” “promise” or similar references to future periods. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the availability and timing of the second tranche under the Avenue Capital financing, Elutia’s ability to raise additional capital, the timing and outcome of FDA review of NXT-41x and the timing and success of the commercial launch of NXT-41x. These forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to us. Additionally, such forward-looking statements are subject to a number of known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied in the forward-looking statements, including, but not limited to: our ability to obtain regulatory approval or other marketing authorizations by the FDA and comparable foreign authorities for our products and product candidates, including NXT-41 and NXT-41x; our ability to successfully develop, acquire and commercialize additional product offerings, including NXT-41 and NXT-41x; our ability to satisfy the conditions required to access the second tranche of the Avenue financing, including raising additional capital on acceptable terms; our ability to achieve or sustain profitability; our ability to service our indebtedness; our ability to regain compliance with Nasdaq’s minimum bid price requirement and otherwise maintain compliance with any other listing requirement of Nasdaq Capital Market, and our ability to maintain a listing of our Class A common stock on the Nasdaq Capital Market; our ability to raise funds in the future in the amounts and at the times needed; and other important factors which can be found in the “Risk Factors” section of Elutia’s public filings with the Securities and Exchange Commission (“SEC”), accessible on the SEC’s website at www.sec.gov and the Investor Relations page of Elutia’s website at https://investors.elutia.com. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. Except as required by applicable law, Elutia expressly disclaims any obligation to publicly update any forward-looking statements.

Investors
Elutia Investor Relations
ir@elutia.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the size and structure of Elutia (NASDAQ: ELUT)'s new financing with Avenue Capital?

Elutia secured a $15 million growth capital loan from Avenue Capital. According to Elutia, $10 million funded at closing, with a second $5 million tranche available upon FDA 510(k) clearance of NXT-41x, aligning capital access with a key regulatory milestone.

How will Elutia (ELUT) use the $15 million loan related to NXT-41x?

Elutia plans to use the loan to fund development and commercialization of NXT-41x. According to Elutia, the financing strengthens its balance sheet, extends cash runway, and is intended to support a strong NXT-41x launch in plastic and reconstructive surgery once clearance is obtained.

When does Elutia expect FDA 510(k) clearance for NXT-41x, and why does it matter for ELUT investors?

FDA 510(k) clearance for NXT-41x is anticipated in the first half of 2027. According to Elutia, this milestone would unlock an additional $5 million loan tranche and enable commercialization in a U.S. plastic and reconstructive surgery market it estimates at $1.5 billion.

How does the Elutia (ELUT) financing affect shareholder dilution and capital structure?

The company states the transaction funds NXT-41x commercialization without an equity offering. According to Elutia, using debt-based growth capital instead of raising equity preserves existing shareholder ownership while still providing $10 million immediately and up to $5 million more after FDA clearance.

What clinical need does Elutia’s NXT-41x target in plastic and reconstructive surgery?

NXT-41x targets high post-operative infection rates in complex plastic and reconstructive procedures. According to Elutia, infection rates can reach 15–20%, and the antibiotic-eluting biomatrix is designed to reduce complications, particularly in soft tissue reinforcement such as breast reconstruction after cancer.

What market opportunity does Elutia (ELUT) see for NXT-41x in the United States?

Elutia estimates a $1.5 billion U.S. market opportunity for NXT-41x in plastic and reconstructive surgery. According to Elutia, the product is intended for procedures with elevated infection risk, potentially positioning it within a large, procedure-driven market once FDA clearance is achieved.